Caracterização imuno-histoquímica de células do infiltrado inflamatório e de citocinas pró e anti-inflamatórias nos carcinomas mamários caninos

Pós-graduação em Medicina Veterinária - FCAV

Haematology and histopathology of Nile tilapia parasitised by Epistylis sp., an emerging pathogen in South America

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Cumulative long-term safety, efficacy and patient-reported outcomes in children with juvenile idiopathic arthritis treated with intravenous abatacept: up to 7 years of treatment

The long-term efficacy and safety of intravenous abatacept in patients (pts) with juvenile idiopathic arthritis (JIA) have been reported previously from the Phase III AWAKEN trial ([1, 2]). Here, we report efficacy, safety and pt-reported outcomes from the open-label, long-term extension (LTE) of AWAKEN, with up to 7 years of follow-up. Pts entered the LTE if they were JIA ACR 30 non-responders (NR) at the end of the 4-month lead-in period (abatacept only), or if they received abatacept or placebo (pbo) in the 6-month double-blind (DB) period. The Child Health Questionnaire was used to evaluate health-related quality of life (HRQoL); physical (PhS) and psychosocial (PsS) summary and pain scores were analyzed. Pain was assessed by parent global assessment using a 100 mm visual analog scale. Efficacy and HRQoL evaluations are reported up to Day 1765 (~ Year 5.5). Safety is presented for the cumulative period (lead-in, DB and LTE), for all pts who received abatacept during the LTE. Of the 153 pts entering the LTE (58 from DB abatacept group, 59 from DB pbo group, 36 NR), 69 completed the trial (29 abatacept, 27 pbo, 13 NR). For pts treated in the LTE, mean (range) exposure to abatacept was 53.6 (5.6–85.6) months. During the LTE, incidence rates of AEs and serious AEs per 100 pt-years were 209.1 and 5.6. Thirty pts (19.6%) had serious AEs; most were unrelated and were musculoskeletal (8.5%) or infectious events (6.5%). No malignancy was reported. There was one death (accidental; unrelated). At Day 169, JIA ACR 50 and 70 response rates were 79.3% and 55.2% in the abatacept group, and 52.5% and 30.5% in the pbo group; 31.0% and 10.2% of pts in the abatacept and pbo groups, respectively, had inactive disease. By Day 1765, JIA ACR 50 and 70 response rates were 93.9% and 78.8% in the abatacept group, and 80.0% and 63.3% in the pbo group; 51.5% and 33.3% had inactive disease. In the NR group, 69.2% and 53.8% of pts achieved JIA ACR 50 and 70 responses at Day 1765, and 30.8% had inactive disease. In pts who entered the LTE, mean baseline PhS scores were below the range for healthy children (abatacept 30.2, pbo 31.0, NR 29.5). At Day 169, 38.3% of pts had reached a PhS score >50 ((1). By the end of the LTE, 43.5% of pts had reached a PhS score >50. At baseline, mean PsS scores for those who entered the LTE were slightly lower than the mean for healthy children (abatacept 43.5, pbo 44.2, NR 47.0). At Day 169, 54.9% of pts had a PsS score >50 (1). By Day 1765, 58.1% of pts had reached a PsS score >50. At baseline, the mean pain score was 42.9. By Day 169, 13.9% of pts were considered pain free (pain score = 0); this was maintained over the LTE (1).

Evaluation of argyrophilic nucleolar organizer regions in oral tumor progression

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?

Objectives. To compare the frequency of another primary malignancy in patients with differentiated thyroid carcinoma (DTC) who received radioiodine therapy or not ((131)I). Material and Methods. 168 cases of DTC patients were retrospectively evaluated as to the frequency of another neoplasia by comparing patients with and without it, taking into account clinical, laboratory, and therapeutic parameters. Results. Another primary malignancy occurred in 8.9% of patients. Of these, 53.3% showed the malignancy before (131)I and 46.7% after it. By comparing both groups, the age at the moment of diagnosis of another neoplasia was 46.1 ± 20.2 years for the group before (131)I therapy and of 69.4 ± 11.4 years for the group after it (P = 0.02). Of the 148 patients treated with (131)I, 4.7% developed another malignancy. The latter were older (61 ± 17 years) than those who did not show another cancer type (44.1 ± 14.2 years) (P < 0.05). Conclusion. The frequency of another neoplasia found after (131)I was similar to that found before (131)I.

Relationship between head and neck cancer therapy and some genetic endpoints

Head and neck cancer (HNC) is the sixth most common human malignancy worldwide. The main forms of treatment for HNC are surgery, radiotherapy (RT) and chemotherapy (CT). However, the choice of therapy depends on the tumor staging and approaches, which are aimed at organ preservation. Because of systemic RT and CT genotoxicity, one of the important side effects is a secondary cancer that can result from the activity of radiation and antineoplastic drugs on healthy cells. Ionizing radiation can affect the DNA, causing single and double-strand breaks, DNA-protein crosslinks and oxidative damage. The severity of radiotoxicity can be directly associated with the radiation dosimetry and the dose-volume differences. Regarding CT, cisplatin is still the standard protocol for the treatment of squamous cell carcinoma, the most common cancer located in the oral cavity. However, simultaneous treatment with cisplatin, bleomycin and 5-fluorouracil or treatment with paclitaxel and cisplatin are also used. These drugs can interact with the DNA, causing DNA crosslinks, double and single-strand breaks and changes in gene expression. Currently, the late effects of therapy have become a recurring problem, mainly due to the increased survival of HNC patients. Herein, we present an update of the systemic activity of RT and CT for HNC, with a focus on their toxicogenetic and toxicogenomic effects.

Oxidative stress and inflammatory response biomarkers in dogs with mammary carcinoma

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeito probiótico do Bacillus amyloliquefaciens no desempenho produtivo e nos parâmetros hematológicos, morfométricos e ultraestruturais do intestino de tilápias-do-Nilo cultivadas em tanque-rede

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Efeitos das formulações nanoestruturadas de doxorrubicina e cisplatina em dispersão de óxido de grafeno reduzido no tratamento da progressão do câncer de bexiga Não-músculo invasivo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Adição de óleo de Citrus sinensis na dieta de tilápia-do-Nilo: desempenho produtivo, perfil hematológico e atividade respiratória de leucócitos

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Correlações entre padrões hematológicos, parasitológicos e desempenho animal de ovelhas suplementadas com gordura protegida

The development of populations of gastrointestinal parasites resistant to antihelmintics has led to seeks new alternatives its control. Stimulation of natural immunity by means of animal nutrition has shown promising results in controlling nematodes in sheep. The addition of protected fat sources, containing essential fatty acids, may be an alternative due to many effects, among them, regulation of immunity expression and regulation of the inflammatory response by immune effectors. The aim of this study was to estimate correlations between haematological and parasitological patterns, animal performance through weight and body condition, under the influence of protected fat in ewes. Fifty Santa Ines sheep, in the final third of pregnancy or postpartum, in paddocks of Panicum maximum, received, individually, 200 g per day of concentrate, isonitrogenous and isocaloric diets, with or without the addition of protected fat. In general, except for total leukocytes and eosinophils, almost all of Pearson correlation coefficients of other variables were significant. However, the protected fat, in the amount offered, had no antihelmintic effect.

Perfil epidemiológico dos participantes do Programa de diagnóstico e prevenção do câncer de boca em Mato Grosso

To determine the profile of the patients who participated in the program of oral cancer diagnosis and prevention in Mato Grosso, from 2008 to 2009. Materials and Methods: The medical records of the treated patients were examined. Results: 1.293 records were analyzed, with a predominance of female patients (60%) and a greater participation of patients from 10 to 19 years of age (20%). Reports of pre-existing illnesses amounted to 302 recorded cases. In addition, 292 variations of normality could be also identified. During the period, 25 participants were recommended for exfoliative cytology and 133 for biopsy, as they presented oral lesions that raised the suspicion of malignancy. Conclusions: Campaigns to raise awareness of and prevent oral cancer are very important and should be extended to the entire population of the state of Mato Grosso, either by means of the local University Center (UNIVAG), or by other agencies and health institutions.

Síndromes paraneoplásicas: o que o cirurgião-dentista precisa saber?

Introduction: the term paraneoplastic is a clinical, biochemical, hormonal, neurological and/or associated disorder with hematologic malignancies, but not directly related to primary tumor invasion and metastasis. Paraneoplatic syndromes may be the first sign of a malignancy. Review of literature: the syndromes that are most commonly related to dentistry are of lambertt-Eaton, Gardner, Cowden disease, Peutz-Jeghers, Sjögren, multiple endocrine neoplasic, multiple neurofibromatosis of Von Recklinghausen, nevoid basal cell carcinoma, acanthosis nigrans and pemphigus paraneoplastic. Conclusion: early diagnosis of malignant neoplasms favors prognosis and paraneoplastic syndromes assist in diagnosis. It is important that surgeons-dentists know these events in order to diagnose them as soon as possible and refer these patients to specialized treatment.

Carcinoma escamoso oral: análise retrospectiva de 185 casos

The squamous cell carcinoma is the most common malignancy in the oral cavity, representing over 90% of cancers in this region. This study aimed to conduct an epidemiological study of oral squamous carcinoma cases diagnosed by the Department of Pathology, Department of Pathology and Clinical Propaedeutics in the Dentistry Faculty of Araçatuba - UNESP, in the period between 1995 and 2005. 185 cases were studied, it was observed that the oral floor and tongue were the sites most affected, with predominance in males, white race and aged between 41 and 60 years, noting that the majority of patients were smokers. Knowledge of these data is important for the dental surgeon to act preventively, contributing to early diagnosis of cancer.

Análise da Frequência de Polimorfismos nos genes IL28B e IL28R1 em pacientes acometidos por Meningioma

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)